Cesar Sommer

🌟 Best of #ASMS2024 🌟 Fintiede Solutions is thrilled to share the groundbreaking advancements unveiled by Evosep at the #ASMS2024 conference in Anaheim! Evosep continues to push the boundaries in the field of proteomics, introducing innovations that are set to transform research and clinical diagnostics. 🔬 Key Innovations Announced: Fully Automated Workflows: - Capable of processing over 500 plasma samples per day. - Maximizes efficiency and minimizes manual intervention. - Ideal for accelerating drug discovery and supporting large-scale translational research. - Reduces cost per sample and environmental impact. Whisper™ Zoom Methods: - Enhances scalability and sensitivity for detailed and accurate proteomic analyses. - Unlocks the ability to detect low-abundant proteins and identify novel biomarkers. - Facilitates deeper biological insights into disease pathways. Evosep Biolabs: Center of Excellence for High Throughput Proteomics: - Specializes in high-throughput proteomics with automated sample preparation. - Offers access to state-of-the-art LC-MS/MS workflows and expert assay development. - Provides scalable capacity for outsourcing proteomics research projects. 🏆 Impact and Vision: Evosep's innovations are designed to make clinical proteomics 100x more robust and 10x faster, revolutionizing the landscape of proteomics research. These advancements are particularly aimed at accelerating drug discovery and enhancing proteomics-based diagnostics, ultimately improving patient care. We are proud to be part of this journey and look forward to the incredible breakthroughs these technologies will enable in the near future. #Evosep #Proteomics #ASMS2024 #ScientificInnovation #DrugDiscovery #TranslationalResearch #Biomarkers #ClinicalDiagnostics #automation #whisper

2

Latest on MDMA rejection; Novo vs. Lilly earnings; Recursion, Exscientia to merge; Q&A with Genentech CEO; and more https://lnkd.in/gRuf3XRp Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up [...] #LosAngeles #OrangeCountyCA #Biotech #Lifescience #News

1

"San Diago... which of course in German means..." (you can fill in the blank in your head if you know the reference 😂) But I AM in gorgeous San Diego! Please reach out if you've been curious about base editing and would like to have an in person seminar in the So Cal region this month! Why base editing for your therapeutic cell engineering pipelines? ⏲️ SAVE TIME- reduce timelines on multiplex edited cell products by up to 90% 💰 SAVE ON COSTS of manufacturing when less steps are required to reach the end product 💪 HEALTHIER CELL PRODUCTS - gene editing with our platform avoids double strand DNA breaks, reducing the risk of genomic translocations, reducing cytotoxicity, and supporting normal growth rates

23

1 Comment

<!-- Content start --> South San Francisco, CA — July 3, 2024 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial (first-line) treatment for people with previously untreated, locally advanced unresectable or metastatic non-squamous non-small cell lung cancer (nSq NSCLC), did not meet its primary endpoints of progression-free survival (PFS) at its primary analysis with a hazard ratio (HR) of 1.27 [95% CI: 1.02,1.57] and overall survival (OS) at its first interim analysis with a HR of 1.33 [95% CI: 1.02, 1.73], which was immature. The combination of tiragolumab plus Tecentriq and chemotherapy showed reduced efficacy in both PFS and OS compared to the comparator arm in the intent-to-treat population, which includes Phase II and Phase III cohorts. The overall safety profile remains consistent with the safety profile previously observed for the combination of tiragolumab plus Tecentriq and chemotherapy, and no new or unexpected findings were identified. Based on these results, patients and investigators will be unblinded and we intend to halt the study. A communication will be sent to the investigators and results will be shared with health authorities and subsequently presented at an upcoming medical meeting. “These results are disappointing as it was our hope that this combination might yield improved outcomes for people living with metastatic non-squamous lung cancer,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “We are thankful to all of the patients and healthcare professionals involved in the study, and we will leverage the learnings to inform our scientific understanding of the anti-TIGIT pathway and new avenues in cancer research.” Ongoing Phase III studies are investigating treatment settings and indications distinct from SKYSCRAPER-06. Based on today’s results, we will evaluate any relevant changes needed to the ongoing tiragolumab program. About SKYSCRAPER-06 study SKYSCRAPER-06 is a global Phase II/III, randomized, placebo-controlled and double-blinded study evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy as an initial (first-line) treatment versus pembrolizumab and chemotherapy in 542 people with non-squamous non-small cell lung cancer. Primary endpoints are overall survival (OS) and progression-free survival (PFS). About tiragolumab Tiragolumab is an investigational novel immune checkpoint inhibitor with an intact Fc region. Tiragolumab selectively binds to TIGIT, a novel inhibitory immune checkpoint which suppresses the immune response to cancer. Based on preclinical research, tiragolumab is thought to work as an immune amplifier with other cancer immunotherapies such as Tecentriq® (atezolizumab). The TIGIT pathway is distinct but

1

Lake N. Paul, PhD. is in San Diego at the Biotechnology Innovation Organization #BIO2024 conference meeting with colleagues & future clients. Connect with him in person to learn about how, as a Collaborative Research Organization, we are best positioned to support your analytical program. #aav #genetherapy #rarediseases #biophysics #STEM #STEMPhilly #biochemistry #celltherapy #bioanalysisllc #PhillyBusiness #phillyscience

9

I wanted to congratulate my coauthors Rashmi Madda, Haichuan Liu and Zoe Zhang on a great technote about multilevel analysis of MMAE conjugated Trastuzumab using Genovis' GlyCLICK® chemistry. Combining the ZenoTOF 7600 with both the Intabio ZT and EAD peptide mapping, comprehensive intact and localized characterization of modifications were achieved. Comparisons between pre and post derivatized Trastuzumab samples identified natural and synthetic modifications allowing for highly accurate monitoring of the payload conjugation reactions. For those interested follow the link below for a PDF copy of the technote https://lnkd.in/eSreFYCz

39

A new #CRISPR-based clinical trial for #SickleCell disease is enrolling at UCSF. This is the first therapy in the U.S. to apply non-viral CRISPR gene editing to directly correct the genetic mutation that causes the disease. Read more: https://ow.ly/Smry50UfZi1

32

Christian Ramirez Amarilla now at #BITS2024 about how inhibiting METTL3, an important RNA methyltransferase, affects RNA structure, adenosine-to-inosine (A-to-I) editing, and the immune response in leukemia models, providing new insights into potential therapeutic approaches for leukemia. #Bioinformatics #LeukemiaResearch #BITS2024

53

Today is the last day of Antibody Engineering & Therapeutics in San Diego! Check out our poster, “Robust and Streamlined Approach for High-Throughput Sequencing of OmniRat Antibody Repertoires.” See our team in booth 300 to continue the conversation! #AntibodyEng

48

1 Comment

My second post this week on the benefit of using recombinant alpaca antibodies is one that touches on an all too familiar topic Cancer. Unfortunately Cancer impacts everyone either directly or indirectly in this world and it has sadly taken a loved one away from the majority of us too soon. Cancer is a complex disease with many different varieties of it and due to such variation clinicians need an array of different tools/strategies to treat and cure the different varieties of Cancer. Scientists around the world who are alot smarter than me have been working hard in their laboratories trying to discover new ways to defeat cancer. Did you know, that these very smart scientists have now discovered that recombinant alpaca antibodies are incredibly useful tools when developing new treatments and cures for Cancer. I recently read the paper below which shows that when you combine recombinant alpaca antibodies with your own immune cells it can result in the destruction of tumors which is really cool and useful in the fight against Cancer. Indeed the very smart scientists found that recombinant alpaca antibodies were better and easier to use than antibodies from other species. This form of treatment approach that the clever scientists used is called CAR-T cell therapy, a rapidly growing area in biopharma and one which Afrobodies is developing recombinant alpaca antibodies for. If you know of anyone working with CAR-T cell therapy please share the research paper below with them so they can see the benefit of working with the coolest molecules in science, recombinant alpaca antibodies or what we Afrobodies more affectionately call Afrobods and the rest of the world calls nanobodies. Our one liner at Afrobodies is "everyone needs an Afrobod" :) Afrobodies September "back to school" offer now allows you to start working with recombinant alpaca antibodies in your own lab for an affordable price. If you are in the UK and want to access Afrobodies incredibly well priced "back to school offer" for nanobody discovery contact our distributor there 2BScientific Ltd. Maybe you can discover the next CAR-T cell therapy for a currently incurable Cancer. Together we will defeat Cancer. Who would have thought that the defeat of cancer would be a team effort between two legged humans and super cute but immensely clever 4 legged alpacas! :) #vhh #alpaca #antibodies #Cancer #therapeutics #singledomain #recombinant #afrobodies https://lnkd.in/d68DKXPQ

1

Passive #LNP tissue targeting paper from Professor James Dahlman's lab. LNP67 was found capable of delivering #mRNA to murine HSCs in vivo, primary human HSCs ex vivo and CD34+ cells in rhesus monkeys in vivo at doses of 0.25 and 0.4 mg kg−1. 

77

2 Comments

Biocom California recently invited Sapient to contribute an article for its Lifelines Magazine edition focused on innovations in #genetherapy and #celltherapy. https://lnkd.in/gC9YfQnM While cell- and gene-based treatments are advancing rapidly, spurred by a landmark year of FDA approvals, their development is not without challenges. We discuss how #multiomics for gene and cell therapy can deliver the novel insights needed to realize the incredible therapeutic potential represented in these pipelines today: https://lnkd.in/gC9YfQnM

21